

EUSAAT2013 Sessions DRAFT 2013

<http://eusaat.org/index.php/congress/2013>

Sunday 15. September

Session 1 – International Activities (Japan), Disease Models & Human-on-a-chip

13:15- 15:15 - 6 lectures (120 min = 20 min each)

#71 - Kojima - ARCH-Tox & MITI 5-year alternatives funding program in Japan

#186 - Spielmann - Peer Review Panel Evaluation of the ROS Photosafety Assay

#93 - Fabri - Vitamin D-dependent antimicrobial pathways in human macrophages

#147 - Weindl - reconstructed skin models mimicking keratinization disorders

#9 - Materne - human on a chip (TU Berlin/TissUse, BMBF Go-Bio project)

#57 – Sacharov - human on a chip (UdSSR Acad Science project)

Session 2 – 3Rs goes 3D

15:45 - 17:45 - 6 lectures (120 min = 20 min each)

#63 - Fritsche - Human Neural Progenitor Cell (hNPC) Aging is mimicked by 3D Cultures

#69 – Kelm - 3-D organotypic iv model systems for liver, cardiac and neuro safety testing

#70 – Angeloni - Blood-brain tumor and air-blood tissue barrier:3D models

#153 – van Acker - Cerium oxide nanoPs air exposure study using human 3D airway model

#78 – Cuddihy - 3D Spheroid Cell Cultures as Models in Drug Discovery

#62 – Liley - Towards replacing in vivo tests of dental and orthopedic implants

Tuesday 17 September 2013

Session 3 – EU Dir 2010/63 - Legal and ethical Aspects

09:00 - 11:00 - 6 lectures (120 min = 20 min each)

#193 – Louhimies - Directive 2010/63/EU: Overview of the work of Commission Expert WGs

#185 – Kluge - Implementation of Directive 2010/63/EU into German law

#13 – Sauer - Ethical review of projects involving non-human primates funded under EU FP7

#161 – Alzmann - Catalogue of Criteria to for Harm-Benefit Analysis in Austria

#61 – Schiffelers - Factors influencing regulatory acceptance and use of 3R models

#56 – Gunatilake - Steps taken to implement 3Rs in research using animals in Sri Lanka

Session 4 – Consequences of the 2013 EU Marketing Ban for Cosmetics & NanoTox

11:30 – 13:30 - 6 lectures (120 min = 20 min each)

#64 - Ates - Retrospective analysis of the mutagenicity/genotoxicity data of EU cosmetics

#171 – Kandarova - Ability of the reconstructed human tissue models to correctly predict phototoxicity and photopotency of topically applied substances and formulations

#17 – Paparella – What do we want to know??

#20 – Taylor - The ADAPT principles for regulatory authorities

#11 – Schindler - Mind the gap. Developing & implementing ITS for nanotoxicology

#33 - Loos - The CAM assay as a model for the development of antitumor nanotherapeutics

Session 5 – Specific Endpoints of Toxicity - Session I

14:30 – 16:30 - 6 lectures (120 min = 20 min each)

#99 – Landsiedel - Hurdles during the development and application of alternative methods

#30 – Madden - Modelling Local and Systemic Toxicity: in siclico & AOPs

#23 - vd Laan – Pharm. & Carcinogenicity. Predictivity to reduce # of carcinogenicity studies

#43 – Seewald - Pre-validation of the ex vivo model PCLS for predicting acute inhalation tox

#54 – Curren - Skin Micronucleus Genotoxicity Assay (RSMN)

#101 – Ramirez - Inter-lab validation of the Yeast Estrogen & Androgen EDS Screens

#99 & 101 = BASF

Session 6 – Tox21 (TT21C) & Specific Endpoints of Toxicity – Session II

17:00 – 18:45 - 5 lectures (100 min = 20 min each)

#29 – Tsaion - Humanizing toxicity testing in the 21st century: who is responsible??

#109 – Westmoreland - 21st Century Safety Science & Non Animal Approaches at Unilever

#81 – Leist - Use of transcriptome profiling in stem cell based test systems for reprotox

#67 - Hoeng - "Assessing the effects of repeated cigarette smoke exposure using human organotypic systems reproducing the respiratory tract in vitro"

#157 – Krug - Integrating transcriptom & metabolom to identify tox-pathways - Parkinson

#81 & 157 = Leist

Wednesday 18. September

Session 7 – Implementing Alternatives into Basic Research

09:00 – 11:00 - 6 lectures (120 min = 20 min each)

#107 – Püschel - Cell culture-based method for determining the activity of the botulinum toxin

#14 – Koch - Laser-based identification of cancer cells and monitoring of cell-agent interact

#66 – Licka - Research in perfused limbs replaces induction of laminitis in live horses

#145 - Weindl - Phase I biotransform: testosterone by human skin and reconstructed skin

#151 – Nastrucci - Alternatives to Animal Experiments in Basic Research and Education: EU

#82 – Grillari - Immortalized primary-like human cells as model systems in nephrotoxicity

Session 8 – Drugs, Vaccines & EU FP7 Projects

11:30 – 13:00 - 5 lectures (90 min = 18 min each)

#47 – Bernau - MRI imaging as an alternative method in safety-testing of veterinary vaccines

#58 – Schmid - New perspectives for realistic and efficient iv screening for inhalable drugs

#40 – Jia - Use of iv cell assays and noninvasive imaging techniques in drug development

#32 – Busquet - The CAAT EU Policy Program in Brussels

#116 – Foerster - An algorithm to determine statistically-valid non-cytotoxic concentrations from imperfect in vitro cytotoxicity data sets